Descrizione del progetto
Uno strumento di screening pionieristico per la rilevazione precoce del cancro della vescica potrebbe salvare milioni di persone
La differenza tra la diagnosi precoce e quella tardiva di un cancro può rappresentare la differenza tra la vita e la morte. A differenza del PAP test regolare per il carcinoma della cervice o della colonscopia per il tumore al colon, non vi è attualmente nessuno strumento efficace di screening per il cancro della vescica e la diagnosi tardiva può avere conseguenza fatali. VISIOCYT ha sviluppato una semplice soluzione software che esamina i comuni vetrini clinici di citologia. Un metodo proprietario per la preparazione, colorazione e osservazione delle cellule viene associato a un algoritmo per l’elaborazione di immagini, al fine di rilevare la presenza localizzata di fluorescenza associata a neoplasia. Gli algoritmi di apprendimento approfondito permettono al software di imparare dai dati senza essere esplicitamente programmato. I finanziamenti dell’UE sostengono la commercializzazione di questa tecnologia riproducibile e ad alto rendimento per la rilevazione precoce del cancro della vescica.
Obiettivo
Bladder cancer is the 5th most common cancer in Europe, with almost 200,000 new cases and 65,000 deaths estimated in 2018. People at high risk for developing this disease include smokers, former smokers, people living in polluted areas, and workers exposed to certain chemicals. The risk of dying from bladder cancer depends on the time of diagnosis and the tumour’s grade: the 5-year survival rate is >95% in early stage cancer, but it drops to <5% in late stage tumours. Besides increased survival, the identification of bladder cancer at its early stages is also associated with easier, less invasive, and cheaper treatment.
Given the importance of early detection and the high incidence of bladder cancer, screening programs for this disease are needed. However, there is no screening tool currently available for bladder cancer. As a solution, VitaDX is developing VisioCyt Screening: a software that combines artificial intelligence algorithms with standard cytology analysis to predict with high accuracy the presence of bladder cancer in patients, even before symptoms appear. Being a software that analyses images obtained through regular clinical procedures, VisioCyt Screening can be readily implemented in centralized labs, resulting in a fast, easy-to-use, reproducible, automated, and high-throughput solution at a low price.
VisioCyt Screening can be classified as an in-vitro diagnostic (IVD) medical device. The global IVD market was estimated at €58 billion in 2018, and is expected to reach €75.2 billion by 2023, with a CAGR rate of 5.2%. In this market, centralized laboratories, which perform large numbers of analyses in few locations and are equipped with the automated systems required by the VisioCyt solution, represent the most relevant target users and customers for VitaDX.
VitaDX is a French SME that combines a strong scientific and clinical background with software and image processing skills and business expertise to develop new diagnostic solutions for cancer.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
35000 RENNES
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.